Development of a new EGFR antibody antagonist which exhibits potential biological effects against laryngeal cancer.

ABSTRACT:

Background

Laryngeal cancer is a common malignant tumor of the head and neck. Clinical treatment methods mainly include radiotherapy and chemotherapy, but the toxicity and side effects of these treatments seriously affect the quality of life of patients. Currently, there are no specific anti-laryngeal cancer drugs available. Therefore, it is necessary to develop new targeted drugs for laryngeal cancer.

Methods

We established a cell model of laryngeal cancer in vitro and a TU686 xenograft model in vivo. We then carried out the related research through a series of experiments [including laser confocal microscopy, enzyme linked immune sorbent assay (ELISA) and Western blot].

Results

The results showed that the epidermal growth factor receptor (EGFR) antibod

SUBMITTER: Ren K 

PROVIDER: S-EPMC8267258 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature